Literature DB >> 29078840

Hepatocellular Carcinoma: A Decade of Hospitalizations and Financial Burden in the United States.

Raxitkumar Jinjuvadia1, Augustine Salami1, Adrienne Lenhart1, Kartikkumar Jinjuvadia2, Suthat Liangpunsakul3, Reena Salgia4.   

Abstract

BACKGROUND: Despite a rise in the prevalence of hepatocellular carcinoma (HCC), data on HCC-related hospitalizations and financial burden are limited. The aim of this study was to evaluate temporal trends of HCC-related hospitalizations and evaluate its financial influence.
MATERIALS AND METHODS: Patients with the diagnosis of HCC, as reported by International Classification of Diseases-Ninth Revision code, were identified from the National Inpatient Sample databases from 2002-2011. The national estimates of hospitalizations were derived using appropriate sample weights. The change in total average charges per each hospitalization over the study period was calculated after adjusting for inflation.
RESULTS: Hospitalizations related to HCC have increased from 24,024 in 2002 to 50,609 in 2011. Of these admissions, HCC was the principal diagnosis in 10,762 and 16,350 subjects in 2002 and 2011, respectively. Most were white males (male: 70%; white: 55%). The overall inpatient mortality was significantly decreased from 13.5% in 2002 to 9.9% in 2011 (P < 0.01). The same trend was also observed for the length of hospital stay (6.5 versus 5.6 days in 2002 and 2011, respectively). The inflation-adjusted cost per hospitalization increased by approximately 47% during the study period.
CONCLUSIONS: Despite the decrease in mortality rate and length-of-stay, hospitalizations and financial burden associated with HCC continued to increase between 2002 and 2011 in the United States.
Copyright © 2017 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Financial burden; Hepatocellular carcinoma; Hospitalizations; Liver cancer; National Inpatient Sample database

Mesh:

Year:  2017        PMID: 29078840      PMCID: PMC5986560          DOI: 10.1016/j.amjms.2017.05.016

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  15 in total

1.  Hospital readmissions among patients with decompensated cirrhosis.

Authors:  Michael L Volk; Rachel S Tocco; Jessica Bazick; Mina O Rakoski; Anna S Lok
Journal:  Am J Gastroenterol       Date:  2011-09-20       Impact factor: 10.864

2.  Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension.

Authors:  Geoffrey C Nguyen; Dorry L Segev; Paul J Thuluvath
Journal:  Clin Gastroenterol Hepatol       Date:  2007-07-10       Impact factor: 11.382

3.  Clinical benefits of hepatocellular carcinoma surveillance: a single-center, hospital-based study.

Authors:  Naota Taura; Keisuke Hamasaki; Kazuhiko Nakao; Tatsuki Ichikawa; Daisuke Nishimura; Takashi Goto; Mariko Fukuta; Hiroshi Kawashimo; Yasuhide Motoyoshi; Hidetaka Shibata; Katsumi Eguchi
Journal:  Oncol Rep       Date:  2005-10       Impact factor: 3.906

4.  Socioeconomic disparities in metabolic syndrome differ by gender: evidence from NHANES III.

Authors:  Eric B Loucks; David H Rehkopf; Rebecca C Thurston; Ichiro Kawachi
Journal:  Ann Epidemiol       Date:  2006-11-29       Impact factor: 3.797

5.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Authors:  Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

Review 6.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

Review 7.  Surveillance for hepatocellular carcinoma.

Authors:  Cristina Della Corte; Massimo Colombo
Journal:  Semin Oncol       Date:  2012-08       Impact factor: 4.929

8.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

9.  The Relationship between Childhood Obesity, Low Socioeconomic Status, and Race/Ethnicity: Lessons from Massachusetts.

Authors:  Robert Rogers; Taylor F Eagle; Anne Sheetz; Alan Woodward; Robert Leibowitz; MinKyoung Song; Rachel Sylvester; Nicole Corriveau; Eva Kline-Rogers; Qingmei Jiang; Elizabeth A Jackson; Kim A Eagle
Journal:  Child Obes       Date:  2015-11-12       Impact factor: 2.992

10.  The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Authors:  Hashem B El-Serag; Jessica A Davila; Nancy J Petersen; Katherine A McGlynn
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

View more
  18 in total

Review 1.  Disease Burden of Hepatocellular Carcinoma: A Global Perspective.

Authors:  Mehmet Sayiner; Pegah Golabi; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 2.  Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians.

Authors:  Alisa Likhitsup; Neehar D Parikh
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

Review 3.  Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review.

Authors:  Abdalla Aly; Sarah Ronnebaum; Dipen Patel; Yunes Doleh; Fernando Benavente
Journal:  Hepat Oncol       Date:  2020-07-21

4.  Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa.

Authors:  Amir Sultan; Chimaobi M Anugwom; Zerihun Wondifraw; Grace A Braimoh; Abate Bane; Jose D Debes
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-08-09       Impact factor: 3.869

5.  Vancomycin prevents fermentable fiber-induced liver cancer in mice with dysbiotic gut microbiota.

Authors:  Vishal Singh; Beng San Yeoh; Ahmed A Abokor; Rachel M Golonka; Yuan Tian; Andrew D Patterson; Bina Joe; Mathias Heikenwalder; Matam Vijay-Kumar
Journal:  Gut Microbes       Date:  2020-03-30

6.  A Nationwide Analysis of Budd-Chiari Syndrome in the United States.

Authors:  Joseph J Alukal; Talan Zhang; Paul J Thuluvath
Journal:  J Clin Exp Hepatol       Date:  2020-08-15

7.  Cost of illness of hepatocellular carcinoma in Japan: A time trend and future projections.

Authors:  Kunichika Matsumoto; Yinghui Wu; Takefumi Kitazawa; Shigeru Fujita; Kanako Seto; Tomonori Hasegawa
Journal:  PLoS One       Date:  2018-06-19       Impact factor: 3.240

8.  No Association Between MicroRNA-608 rs4919510 G>C Polymorphism and Digestive System Cancers Susceptibility: A Meta-Analysis Based on 10,836 Individuals.

Authors:  Xue-Feng Li; Ju-Kun Song; Jun-Wei Cai; Yu-Qin Zeng; Min Li; Jie Zhu; Yu-Ming Niu
Journal:  Front Physiol       Date:  2018-06-07       Impact factor: 4.566

Review 9.  Public Health Considerations among People who Inject Drugs with HIV/HCV Co-Infection: A Review.

Authors:  Rachel M Murdock; Marisa B Brizzi; Omar Perez; Melissa E Badowski
Journal:  Infect Dis Ther       Date:  2019-01-03

10.  Long noncoding RNA highly upregulated in liver cancer promotes the progression of hepatocellular carcinoma and attenuates the chemosensitivity of oxaliplatin by regulating miR-383-5p/vesicle-associated membrane protein-2 axis.

Authors:  Peng Li; Yuwei Li; Lieting Ma
Journal:  Pharmacol Res Perspect       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.